Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial

Publisher： Karger

E-ISSN： 2296-5262|34|3|101-108

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.3, 2011-02, pp. : 101-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy of Peritoneal Carcinomatosis with Catumaxomab

By  

Oncology Research and Treatment, Vol. 34, Iss. 3, 2011-02 ,pp. : 86-87

Karger

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Sequential erlotinib with gemcitabine in NSCLC

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 1, 2015-03 ,pp. : 4-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 191, Iss. 2, 2018-02 ,pp. : 229-239

John Wiley & Sons Inc

Access to resources Recommend Favorite